Hal V. Barron is President, Research and Development, at Calico, a Google-back biotechnology company focused on the aging process. Dr. Barron was most recently Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Hoffmann-La Roche. Dr. Barron joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions of increasing responsibility and leadership within cardiovascular research and specialty therapeutics. In 2002, Dr. Barron was promoted to Vice President of Medical Affairs. In 2003, he became the Senior Vice President of Development and in 2004 he was appointed Chief Medical Officer. In 2009, he was appointed Executive Vice President. Dr. Barron previously served as a director and member of the compensation committee of Alexza Pharmaceuticals Inc., a public pharmaceutical company, from December 2007 to May 2013. Prior to joining Genentech, Dr. Barron received his B.S. in Engineering Physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California, San Francisco. Dr. Barron’s academic positions include Associate Adjunct Professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.